Main Conference Day 2 - CET (Central European Time, GMT+01:00)
Main Conference Day 2 - CET (Central European Time, GMT+01:00)
search
07:30 - 08:0030 mins
Morning Spotlight Presentation
Electrostatic Drying Technology and Solvent-Based Therapeutics - Solvent Removal and Drying in a One-Step Process
- Jyothi Rangineni, PhD - Senior Process Scientist, Fluid Air
08:00 - 08:055 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairpersons Remarks: Oligonucleotide Preclinical and Clinical Updates
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
08:00 - 08:055 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairwoman's Remarks: Case Studies of Innovations and Efficiencies in Oligonucleotide CMC
- Sonja Merkas, Ph.D. - Founder, Livinovea
08:00 - 08:055 mins
Peptide Discovery to CMC
Chairman’s Remarks: Trends in Peptide Discovery and Synthesis
- Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
08:05 - 08:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
New Weapons Against Multidrug Resistant Bacterial Infections via an RNA Therapeutics Antibiotic Drug Discovery Platform
- Peter Nielsen, PhD - Professor, University of Copenhagen
08:05 - 08:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Scaling Up Solution Phase Oligo Manufacturing and Future Innovations
- Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
08:05 - 08:3530 mins
Peptide Discovery to CMC
Discovery and Development of Disulfide-constrained Peptides
- Christina Schroeder, Ph.D. - Senior Fellow, Peptide Therapeutics, Genentech
08:35 - 09:0530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Using the L-stereoisomer RNA Aptamer NOX-A12 to Enhance Efficacy in Solid Tumors
- Aram Mangasarian, Ph.D. - Chief Executive Officer, TME Pharma
08:35 - 09:0530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
.Biocatalytic Approaches to Oligonucleotides Manufacturing, a CMC Perspective
- Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
08:35 - 09:0530 mins
Peptide Discovery to CMC
Development of Membrane-Permeable Cyclic Peptides
- Christian Heinis, PhD - Associate Professor, Ecole PolyTechnique Federale de Lausanne
09:05 - 09:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Antisense Oligonucleotides for Treatment of Cancer and Kidney Diseases
- Frank Jaschinski, PhD. - Chief Scientific Officer, Secarna Pharmaceuticals
09:05 - 09:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Designing a Safe, Sustainable, and Efficient Drug Manufacturing Processes for Oligonucleotide Based Products
- Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
09:05 - 09:3530 mins
Peptide Discovery to CMC
Targeting Membrane-bound Proteins Using Cell-based Biopanning of Cyclized CLIPS™ Peptides in Phage-displayed Libraries
- Sheena Ong, PhD - Scientist, Biosynth
09:35 - 10:1540 mins
Networking Refreshment Break in Poster and Exhibit Hall
10:15 - 10:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
RNA Therapies in Heart Failure - An Update
- Janika Viereck, PhD - Head of R&D, Cardior Pharmaceuticals GmbH - a Novo Nordisk company
10:15 - 10:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Plant Design and Manufacturing Challenges with Insights from Leqvio
- Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
10:15 - 10:4530 mins
Peptide Discovery to CMC
Development of HER-096 as a Disease Modifying Therapy for Parkinson’s Disease
- Antti Vuolanto - Chief Executive Officer, Herantis Pharma plc
10:45 - 11:1530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Clinical Update on Rugonersen
- Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
10:45 - 11:1530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
NMR Platform Methods for Content and Loop Structure of Oligonucleotides
- Joan Malmstrøm, Ph.D. - Principal Scientist, CMC Analytical Support, Novo Nordisk A/S
10:45 - 11:1530 mins
Peptide Discovery to CMC
Development of GUBamy, A Clinical Stage Long-acting Amylin Analogue Formulated at Neutral pH, Using StreaMLine - A ML-driven Peptide Drug Discovery Platform
- Morten Lundh, Ph.D. - Director, Drug Discovery Innovation, Gubra A/S
11:15 - 11:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Oligonucleotide IMT504, a Drug Candidate for Complex Regional Pain Syndrome. Preclinical and Phase-I Clinical Results
- Alejandro Montaner - CEO, Immunalgia Therapeutics
11:15 - 11:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Process Development & Manufacturing of Oligos
- Sonja Merkas, Ph.D. - Founder, Livinovea
- Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
- Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
- Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
- Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
11:15 - 11:4530 mins
Peptide Discovery to CMC
Targeted Innate Immune Stimulators as Therapeutics
- Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
11:45 - 11:505 mins
Transition to Spotlight Presentations
11:50 - 12:2030 mins
Spotlight Presentation 1
Oligo Manufacturing Innovations - From Synthesis through Concentration
- Tom Krebstakies, PhD - Sales Manager - Europe & Asia, Asahi Kasei Bioprocess
11:50 - 12:2030 mins
Spotlight Presentation 2
Streamline Your Nucleic Acid Therapeutics Development and Manufacturing
- Charlotte LeKieffre, PhD - Biopharma Application Specialist, Agilent Technologies
- Ralph Beneke - Product Specialist, Genomics, Agilent Technologies
- Amanda Haas - Business Development Manager, Gene Editing Therapeutics, Agilent Technologies
11:50 - 12:2030 mins
Spotlight Presentation 3
New Trends in Oligotherapeutics
- Daniel Bachmann, PhD - Business Development Manager, Bachem AG
12:20 - 13:2565 mins
Networking Luncheon in Poster and Exhibit Hall
- Kangming Chen, PhD - Head of mRNA & Plasmid Department, GenScript
- Jiazhen Liang, PhD - Senior Scientist, GenScript
13:25 - 13:5530 mins
Spotlight Presentation 1
The Latest Tools for the Characterization of mRNA and Oligonucleotide Biopharmaceuticals by CE and LC-MS
- Stephen Lock, PhD - Senior Market Development Manager, SCIEX
13:25 - 13:5530 mins
Spotlight Presentation 2
Advancing Oligonucleotide Process Development: Integrating First Principles for Process Characterization
- Jale Muslehiddinoglu, PhD - Vice President of Strategic Innovation, ST Pharm
13:25 - 13:5530 mins
Spotlight Presentation 3
New LC-MS Approaches for RNA Therapeutics to Ensure Process Consistency and Product Quality
- Jonathan Fox - Consulting Scientist, Waters Corporation
13:55 - 14:005 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman's Remarks: Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical
- Troels Koch, PhD - Chief Technology Officer, MiNa Therapeutics
13:55 - 14:005 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairman's Remarks: Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs
- Daniel Waschke, Ph.D. - Technical Regulatory Manager, F. Hoffmann-La Roche Ltd.
13:55 - 14:005 mins
Peptide Discovery to CMC
Chairman’s Remarks: Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls
- Riccardo Bernasconi, Ph.D. - Director Business Development, Bachem
14:00 - 14:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Developing RNA Editing As a New Class of Medicine: From Mechanism to Therapeutic Applications
- Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics
14:00 - 14:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
An Update on EMA Regulatory Guidelines for Oligonucleotides
- René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
14:00 - 14:3030 mins
Peptide Discovery to CMC
How to Develop a Close-to-commercial Manufacturing Process for Peptide Drug Substance
- Gajan Santhakumar, Ph.D. - Associate Principal Scientist, Early Chemical Development, AstraZeneca
14:30 - 15:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Increasing ASO Stability with Chemical Modifications
- Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
14:30 - 15:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
How to Prepare for a Successful IND/IMPD When Developing Oligonucleotide Therapeutics
- Hagen Cramer, PhD - Chief Technology Officer, QurAlis
14:30 - 15:0030 mins
Peptide Discovery to CMC
Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand
- Olivier Ludemann-Hombourger, PhD - Director, Global Innovation and Technology, PolyPeptide Group
15:00 - 15:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Fatty Acid Conjugation to Enable Oligonucleotide Delivery into the CNS
- Beatriz Llamusi, PhD - Chief Executive Officer & Co Founder, Arthex Biotech S.L.
15:00 - 15:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
General Post-approval Observations and Trends in Oligo Programs from a Regulatory Perspective
- Tracey Burr, Ph.D. - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
15:00 - 15:3030 mins
Peptide Discovery to CMC
A Generalized PAT Approach for Fast Peptide Purification Process Development and Production Control in CMC Settings
- Jörg Kittelmann, Ph.D. - Principal Scientist, CMC Downstream API Development, Novo Nordisk
15:30 - 16:1545 mins
Networking Refreshment Break in Poster and Exhibit Hall
- Sophie Corbet - EMEA Bioprocessing Technical Service Manager, DuPont
- Mathew Miller, PhD - Director, Life Science and RNA Technologies, Codexis
16:15 - 16:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
AIC468 - A Novel Antisense Oligonucleotide in Clinical Development for Treatment of BKV Infections
- Eric van der Veer, PhD - Chief Innovation Officer, Hybridize Therapeutics
- Tamara Pfaff - Head of Preclinical Development, AiCuris Anti-infective Cures AG
16:15 - 16:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Regulatory CMC Insights on Post-approval Changes for a siRNA Oligonucleotide
- Daniela Fischer, Ph.D. - Associate Director Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing
16:15 - 16:4530 mins
Peptide Discovery to CMC
A Second-generation Process for the Manufacturing of Liraglutide
- Alexander Kleinsmann, PhD - Director R&D, CMC Development, Bachem AG
16:45 - 17:1530 mins
Oligonucleotide Discovery, Preclinical and Clinical
State of the Art siRNA - Delivery and Chemistry
- Tomaz Einfalt, PhD - Principal Investigator II xRNA, Novartis Institutes for BioMedical Research
16:45 - 17:1530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Enzymatic Ligation, Regulatory Challenges and Potential Platform Approaches
- Sergey Tsukanov, Ph.D. - Senior Director Chemistry, Eli Lilly and Company
16:45 - 17:1530 mins
Peptide Discovery to CMC
Optimizing Critical Peptide Impurity Management through Design of Experiments
- Yi Yang, PhD - Lead Scientist, Ferring Pharmaceuticals A/S
17:15 - 19:00105 mins
Evening Networking Reception in Hamburg
19:00 - 19:055 mins
Close of Day Two
* 活动内容有可能不事先告知作更动及调整。